Angiolymphatic invasion as a prognostic fator in resected N0 pancreatic adenocarcinoma

BACKGROUND: Pancreatic adenocarcinoma remains one of the worst digestive cancers. Surgical resection is the main target when treating a patient with curative intent. AIM: To assess angiolymphatic invasion as a prognostic factor in resected pN0 pancreatic cancer. METHODS: Thirty-eight patients were s...

Descripción completa

Detalles Bibliográficos
Autores principales: de ALMEIDA, Ricardo Vitor Silva, PACHECO-JR, Adhemar Monteiro, SILVA, Rodrigo Altenfelder, de MORICZ, André, de CAMPOS, Tércio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Colégio Brasileiro de Cirurgia Digestiva 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424686/
https://www.ncbi.nlm.nih.gov/pubmed/28489168
http://dx.doi.org/10.1590/0102-6720201700010012
Descripción
Sumario:BACKGROUND: Pancreatic adenocarcinoma remains one of the worst digestive cancers. Surgical resection is the main target when treating a patient with curative intent. AIM: To assess angiolymphatic invasion as a prognostic factor in resected pN0 pancreatic cancer. METHODS: Thirty-eight patients were submitted to pancreatoduodenectomy due to head pancreatic cancer. Tumor size, margins, lymph nodes, pTNM staging, angiolymphatic and perineural invasion were described in the pathologists' reports. RESULTS: Most patients were female. Overall median survival was 13 months. Gemcitabine was the regimen of choice for chemotherapy in selected patients; however, it did not improve overall survival. pR0 resection had better survival compared with pR1. Within the pN0 group, survival was significantly better in patients without angiolymphatic invasion. CONCLUSION: Angiolymphatic invasion in N0 pancreatoduodenectomy can be demonstrated by the Hematoxylin-Eosin stain and may predict a poor prognosis factor for those patients.

Ejemplares similares